Fig. 2From: Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trialWaterfall plot of the best percentage change from baseline in measurable tumor lesions of 28 measurable patients (A) and duration of response (n = 28) (B)Back to article page